Clinico-Hematological Spectrum of Non-Leukemic Myeloproliferative Disorder

Ahtasham  Akbar; Roshan  Afshan MD; Muhammad  Asif; Pir Sabir  Shah; Dua  Zhaira

doi:10.54112/bcsrj.v6i1.1544

Authors

Ahtasham Akbar Comsats University Islamabad, Pakistan
Roshan Afshan MD Detroit Medical Center Wayne state University, USA
Muhammad Asif Shifa College of Medical Technology, Shifa Tameer-E-Millat University, Pakistan
Pir Sabir Shah Riphah International University, Rawalpindi, Pakistan
Dua Zhaira Riphah International University, Rawalpindi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i1.1544

Keywords:

Mean Cell Volume, Lactate Dehydrogenase, Mean Cell Hemoglobin, Myelo-Proliferative Neoplasm

Abstract

Myeloproliferative neoplasms (MPNs) are a group of hematological disorders originating from marrow stem cells, characterised by clonal proliferation of hematopoietic components. The three primary non-leukemic MPNs include Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF). These disorders affect the bone marrow, liver, and spleen, leading to various clinical manifestations. Limited data on MPNs in Pakistan necessitates further research to understand their prevalence and demographic distribution. Objective: To assess the spectrum, prevalence, and demographic distribution of non-leukemic MPNs among patients at Benazir Bhutto Hospital, Rawalpindi. Methodology: A retrospective study was conducted over three to four months at Benazir Bhutto Hospital, Rawalpindi. Patient data were analysed using SPSS Version 25, focusing on categorical variables such as age, gender, and MPN type. The diagnosis of MPNs was based on clinical, hematological, and cytogenetic criteria by the 2016 WHO classification. Results: 26 patients were diagnosed with non-leukemic MPNs, with a male-to-female ratio of 1.4:1. Among these, 15 males (58%) and 11 females (42%) were affected. Polycythemia Vera was diagnosed in 7 patients (27%), Essential Thrombocythemia in 9 patients (35%), and Primary Myelofibrosis in 7 patients (27%). Three patients (11%) were classified as MPN-Unclassified. Conclusion: The study highlights the demographic distribution and prevalence of non-leukemic MPNs in a tertiary care hospital in Pakistan. These findings emphasise the need for clinical and hematological evaluations and cytogenetic testing for accurate diagnosis. Further genetic and environmental studies are required to explore regional MPN prevalence and pathogenesis variations.

Downloads

Download data is not yet available.

References

Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chemico-biological interactions. 2010;184(1-2):16-20.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, et al. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;106(3):631-5.

Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation–negative erythrocytosis. New England Journal of Medicine. 2010;363(12):1189-90.

Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, The Journal of the American Society of Hematology. 2007;110(3):840-6.

Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia research. 2011;35(2):177-82.

Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. British journal of haematology. 2007;138(3):354-8.

Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109(11):2279-84.

Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance. British journal of haematology. 2005;131(2):208-13.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for the diagnosis and management of myelofibrosis. British journal of haematology. 2012;158(4):453-71.

Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. British journal of haematology. 2011;153(2).

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. The American journal of medicine. 2004;117(10):755-61.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. Journal of clinical oncology. 2011;29(23):3179-84.

Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. American journal of hematology. 1999;61(1):10-5.

Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. American journal of hematology. 2012;87(3):284-93.

Zhang Z-R, Duan Y-C. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. Asian Pacific Journal of Cancer Prevention. 2014;15(4):1681-4.

Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. American journal of hematology. 2013;88(8):665-9.

Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. British journal of haematology. 2013;162(6):730-47.

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood, The Journal of the American Society of Hematology. 2012;120(26):5128-33.

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, The Journal of the American Society of Hematology. 2009;113(20):4829-33.

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, The Journal of the American Society of Hematology. 2010;115(9):1703-8.

Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: comparison with the 2008 version. American journal of hematology. 2017;92(4):E48-E51.

Andreasson B, Löfvenberg E, Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. European journal of haematology. 2005;74(6):489-95.

Rojer R, Mulder N, Nieweg H. ‘Classic’and ‘Acute’Myelofibrosis: A Retrospective Study. Acta Haematologica. 1978;60(2):108-16.

Simonović E, Mačukanović-Golubović L, Milenović M, Mladenović M, Colić V. Basic biochemical parameters significant in diagnosis of myeloproliferative diseases. MPS. 2007;26:11.88.

Michiels J, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. The Netherlands journal of medicine. 1999;54(2):46-62.

Rudzki Z, Kawa R, Okoñ K, Szczygieł E, Stachura J. Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool. Virchows Archiv. 2006;448:59-67.

Tang G, Lopez JEH, Wang SA, Hu S, Ma J, Pierce S, et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017;102(9):1511.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W, editors. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Seminars in thrombosis and hemostasis; 2006: Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ….

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology. 2005;23(10):2224-32.

Knoops L, Hermans C, Ferrant A, Constantinescu SN. Clinical implications of JAK2 mutations in myeloproliferative disorders. Acta Clinica Belgica. 2008;63(2):93-8.

Shaikh MS, Shaikh MU, Adil SN, Khurshid M, Ahmed ZA. Clinico-pathological profile and outcomes of patients with polycythaemia vera, essential thrombocythaemia and idiopathic myelofibrosis: a tertiary care center experience from southern Pakistan. Journal of Ayub Medical College. 2016;28(2):293.